Efficacy of Alefacept Treatment in Chronic Plaque Psoriasis

July 1, 2003

Alefacept is a human LFA-3/IgG1 fusion protein incorporating the external domain of LFA-3, which is expressed on the surface of APCs.4 Alefacept acts by blocking the interaction between LFA-3 and CD2 on the surface of T cells, thereby interfering with the costimulatory step of T-cell activation.